US 11,998,765 B2
Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery
Gholam A. Peyman, Sun City, AZ (US); Michael Kolios, Toronto (CA); Celina Yang, Toronto (CA); Jahangir Tavakkoli, Toronto (CA); Elyas Shaswary, Toronto (CA); Hisham Assi, Toronto (CA); and Joseph Carl Kumaradas, Toronto (CA)
Assigned to Cancer Rx, LLC, Sun City, AZ (US)
Filed by Cancer Rx, LLC, Sun City, AZ (US)
Filed on Sep. 29, 2021, as Appl. No. 17/489,655.
Claims priority of provisional application 63/085,007, filed on Sep. 29, 2020.
Prior Publication US 2022/0096873 A1, Mar. 31, 2022
Int. Cl. A61N 7/02 (2006.01); A61K 31/7048 (2006.01); A61K 41/00 (2020.01); A61N 5/06 (2006.01); A61N 5/067 (2006.01); A61N 7/00 (2006.01); A61B 5/00 (2006.01)
CPC A61N 7/02 (2013.01) [A61K 31/7048 (2013.01); A61K 41/0033 (2013.01); A61K 41/0042 (2013.01); A61N 5/062 (2013.01); A61N 5/067 (2021.08); A61B 5/0095 (2013.01); A61N 2005/0627 (2013.01); A61N 2007/0004 (2013.01); A61N 2007/0082 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A cancer treatment method using ultrasound energy for targeted drug delivery, the method comprising the steps of:
administering a plurality of nanocarriers to a patient in need thereof so as to target a tumor in the patient, the administered nanocarriers containing an anti-tumor medication; and
exciting the nanocarriers in a first non-thermal ultrasound mode and/or a second thermal ultrasound mode using an ultrasound source that generates a non-thermal ultrasonic wave and/or a thermal ultrasonic wave so as to release the anti-tumor medication from one or more of the plurality of nanocarriers at a site of the tumor;
wherein the ultrasound source is a therapeutic ultrasound transducer; and
wherein the step of exciting the nanocarriers further comprises exciting the nanocarriers using the therapeutic ultrasound transducer in the first non-thermal ultrasound mode, the therapeutic ultrasound transducer emitting pulsed high intensity focused ultrasound (pHIFU) for mechanical excitation of the plurality of nanocarriers in the first non-thermal ultrasound mode so as to release the anti-tumor medication from the nanocarriers by rupturing membranes of the nanocarriers and/or peeling a polymer coating off the nanocarriers.